Overview

PROACTIVE: Preventing Acute/Chronic GVHD With TocIlizumab Combined With GVHD Prophylaxis Post allogEneic Transplant

Status:
Active, not recruiting

Trial end date:
2023-04-01

Target enrollment:

Participant gender:

Summary

This is a phase II open-label trial designed to evaluate the efficacy of tocilizumab in improving GVHD-free/relapse-free survival (GRFS) after allogeneic hematopoietic cell transplantation (alloHCT) for hematologic malignancy.

Phase:

Phase 2

Details

Lead Sponsor:

Medical College of Wisconsin

Treatments:

Methotrexate
Tacrolimus